Apellis Pharmaceuticals shares rally as competing eye treatment fails to impress analysts
Apellis Pharmaceuticals Inc. shares (APLS) jumped 8% premarket on Tuesday after competitor Iveric Bio, a unit of Astellas Pharma Inc. (4503.TO), on Monday released results of a trial of Izervay as a treatment for geographic atrophy, a form of age-related macular degeneration. Based on the new data, Izervay's "efficacy is totally unclear and safety got worse," Raymond James analysts wrote in a note Monday. The analysts maintained a strong buy rating on shares of Apellis, whose geographic atrophy treatment Syfovre was approved by the U.S. Food and Drug Administration early this year. Syfovre has also been dogged by safety concerns, but Apellis late last month identified a certain type of needle as a potential cause of inflammation of retinal vessels seen as a rare but serious side effect of the eye treatment. Apellis shares have dropped 9% in the year to date, while the S&P 500 has gained 16%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-19-23 0839ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks